Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment

From BioPortfolio: – Pfizer advancing SB-525 for Hemophilia A to a Phase 3 registrational study in 2020 Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of…

Read the full article here

Related Articles